ITM ISOTOPE TECHNOLOGIES MUNICH SE |

ITM ISOTOPE TECHNOLOGIES MUNICH SE

ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline combining its high-quality radioisotopes with targeting molecules to develop precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.

For more information please visit: www.itm-radiopharma.com

ITM at a glance:

Field of Activity	Oncology, Precision Medicine, Targeted Radionuclide Therapy, Nuclear Medicine, Theranostics
Technology	Targeted Radionuclide Therapy (TRT) is an emerging class of cancer therapeutics, seeking to deliver radiation by intravenous infusion directly to the tumor while minimizing radiation exposure to healthy tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (peptide, antibody, small molecule) that can precisely recognize tumor cells resulting in the accumulation of the radioisotope at the tumor site and the release of a small amount of radiation, that can destroy tumor tissue. The targeting molecule can be used in a “theranostic” approach for diagnosis (targeting molecule is linked with a diagnostic radioisotope) and for therapy (linked with a therapeutic radioisotope). This allows tumors and metastases to be both precisely localized at an early stage, and subsequently treated following the same mechanism.
Products/Services	1) Development of targeted radiopharmaceuticals for cancer treatment Our lead candidate ITM-11 (n.c.a. 177Lu-edotreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is currently under investigation in two phase III clinical trials, COMPETE and COMPOSE. ITM-11 is a Targeted Radionuclide Therapeutic consisting of the high-quality radioisotope no-carrier-added lutetium-177 chelated to a somatostatin analogue to specifically target GEP-NETs. 2) Therapeutic & diagnostic radioisotopes 3) Equipment for Radiolabeling & Quality Control: iQS-Theranostics Synthesizer, iQS® Ga-68 Fluidic Labeling Module, Consumables (Reagent Sets, Cassettes), Quality Control Solution (radio-HPLC) 4) GMP Radiolabeling Service
Unique Selling Point	ITM is an established company with a proven history as a radioisotope manufacturer and supplier and an emerging leader as a radiopharmaceutical company with a strong precision oncology drug development program including two phase III clinical trials. We are leveraging our expertise in drug development, GMP manufacturing, commercialization and global supply logistics for both diagnostic and therapeutic radioisotopes and radiopharmaceuticals to meet the needs of healthcare professionals and their patients across the globe.
Date of Incorporation/ Number of Employees	2004/350

Contact:

Address	Lichtenbergstr. 1 85748 Garching/Munich
Telephone	+49 89 329 8986-6000
E-Mail	info@itm-radiopharma.com
Web Address	www.itm-radiopharma.com
Social Media	LinkedIn Twitter Facebook

ARTIKEL ZU DIESEN SCHLAGWORTEN